Anti-erythropoietin antibodies and pure red cell aplasia.
about
Acquired pure red cell aplasia: updated review of treatmentImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsBiosimilar insulins: guidance for data interpretation by clinicians and usersPure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A.Paraneoplastic syndromes: an approach to diagnosis and treatment.2D-LC analysis of BRP 3 erythropoietin N-glycosylation using anion exchange fractionation and hydrophilic interaction UPLC reveals long poly-N-acetyl lactosamine extensions.Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).Potential impact of subsequent entry biologics in nephrology practice in Canada.Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectTwo different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.Epoetin beta in oncology: examining the current evidence.Current and future options for the treatment of chemotherapy-induced anaemia.EMEA guidelines on biosimilars and their clinical implications.Use of agents stimulating erythropoiesis in digestive diseasesBiosimilars: current status and future directions.Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.How safe is renal replacement therapy? A national study of mortality and adverse events contributing to the death of renal replacement therapy recipients.HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.Ten year follow up of erythropoietin induced autoimmune pure red cell aplasia.Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation.Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.Erythropoietin diminishes isoflurane-induced apoptosis in rat frontal cortex.Safety of high-dose recombinant erythropoietin in a neonatal rat model.Epoetin-β induced pure red cell aplasia: an unintended consequence.A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.Safety of Polysorbate 80 in the Oncology Setting.
P2860
Q24652253-33DC7ACC-912D-40E4-8E82-82F1E72A59AEQ26738810-C015220D-BC2F-4725-95ED-4553A9E0C6E8Q26992066-ED96877B-6F8A-4196-8288-BF000E5A526FQ33905622-1AB4B628-1C5E-4C91-B7F0-2E2C1370E278Q34135478-ACF21755-1389-4546-9143-1E2BCC695111Q35017132-A04FA08E-0CA3-4740-809E-ADEA8ACD5579Q35119023-412E394F-DFA2-49D7-B4BC-56732A3E96DCQ35146196-C98D43A8-2EF4-4FE1-B7F2-B3CF1EB96BEFQ35847694-6FDEC158-7311-4C61-BDCA-6B0C6CDA5B18Q35851261-21B415A1-DB82-49A8-990D-3BDA00A209E2Q36188312-DE72325E-2134-466F-B4D4-ACB5543F5F2BQ36194596-C169B726-87BD-4B46-8449-FA1154ABE5B1Q36429666-3EB30409-109F-4BC9-A67D-600BDB8586C6Q36568736-6D857A0F-8A28-4B89-B800-9901B879541CQ36921823-A4AE1238-7AE6-4507-B0CA-F3EB706912F8Q37368733-13A662AC-70F6-4A45-B388-364ABA0FC09BQ37729154-65642B27-1809-4C5D-9BC9-488786D2BC3CQ38046652-669834EA-3233-4A7A-876D-6E30579AAF86Q38143795-11D5E744-BE9A-45AE-A93F-4CA449249E7EQ38666170-810B4D7F-52B6-4576-9D39-9779007CF0FFQ38844794-4BB7283D-4BCE-4856-917C-347DF54F2C9FQ41905239-111D1F7C-EA33-43B7-8058-19A7CB070527Q42239843-855FF1A6-111C-42B8-95FC-4205EF06778BQ44198225-D81454DA-6735-430E-A30C-9B46A53F9B22Q46081433-A13E5EA5-918A-4199-B0DE-B5B5A6E06439Q46807825-BC7DA524-2232-4324-B647-849485BB358BQ47111895-4D04E5A0-1682-49DD-A885-DBD3FDDEA578Q47585377-35BBF3D5-E3C7-4BA8-BDF5-71EBBCC829C4Q48250618-9F6CF1CF-2B8A-48D1-944E-DBBC8575E49AQ50221780-206D7208-5592-4BDA-AC3C-FD2A836DF1BEQ50501091-08175034-6CB3-43D3-A54B-11A89862C797Q50654749-2D589679-A48B-4202-A484-D9A58B9DFB63Q53583192-B10222BB-1CF2-4AC2-A8E0-C852EE550FD5Q53804522-3736945E-4D4A-4D41-ADC5-35E12A1D82C2Q55405018-D6E5F823-71F5-4B78-904A-DB3038F4F2A5
P2860
Anti-erythropoietin antibodies and pure red cell aplasia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Anti-erythropoietin antibodies and pure red cell aplasia.
@ast
Anti-erythropoietin antibodies and pure red cell aplasia.
@en
type
label
Anti-erythropoietin antibodies and pure red cell aplasia.
@ast
Anti-erythropoietin antibodies and pure red cell aplasia.
@en
prefLabel
Anti-erythropoietin antibodies and pure red cell aplasia.
@ast
Anti-erythropoietin antibodies and pure red cell aplasia.
@en
P2093
P1476
Anti-erythropoietin antibodies and pure red cell aplasia.
@en
P2093
Jerome Rossert
Kai-Uwe Eckardt
Nicole Casadevall
P304
P356
10.1097/01.ASN.0000107561.59698.42
P577
2004-02-01T00:00:00Z